Craft

RespireRx Pharmaceuticals

Stock Price

$0

2024-10-29

Market Capitalization

$613.3 K

2024-10-29

Revenue

$86.9 K

FY, 2015

RespireRx Pharmaceuticals Summary

Company Summary

Overview
RespireRx Pharmaceuticals Inc. (formerly Cortex Pharmaceuticals, Inc.) is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. All of the Company’s current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress.
Type
Public
Status
Active
Founded
1988
HQ
Glen Rock, NJ, US | view all locations
Website
http://respirerx.com/
Cybersecurity rating
Sectors

Key People

  • Kathryn MacFarlane, Director

    • Tim Jones

      Tim Jones, President, Chief Executive Officer, Member of Board of Directors

      • Arnold Lippa, Executive Chairman and Chief Scientific Officer

        • Arnold S. Lippa

          Arnold S. Lippa, Chief Scientific Officer, Executive Chairman of Board of Directors

          Operating MetricsView all

          Pre-Clinical Phase Products

          1

          FY, 2016

          Phase II Trials Products

          4

          FY, 2016

          Phase I Trials Products

          1

          FY, 2016

          LocationsView all

          1 location detected

          • Glen Rock, NJ HQ

            United States

            126 Valley Rd

          RespireRx Pharmaceuticals Financials

          Summary Financials

          Net income (Q3, 2023)
          ($395.5K)
          Cash (Q3, 2023)
          $6.4K
          EBIT (Q3, 2023)
          ($332.5K)
          Enterprise value
          $1.8M

          Footer menu